



U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

~~Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.~~

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	10/038,006
Filing Date	January 4, 2002
First Named Inventor	Dudley, D.A. et al
Art Unit	1624
Examiner Name	
Attorney Docket Number	5711-DI-01

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	†
		Country Code ² Number ⁴ Kind Code ³ (if known)	MM-DD-YYYY			
RR		WO 98/13368 A1	04/02/1998	Astra Aktiebola		
AP		JP 63-301874	12/08/1988	Fujisawa Pharma		

**Examiner
Signature**

Date
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

#4

Sheet 1 of 2

FORM PTO-1449 (Rev. 2-32) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 5711-D1-01-MG	SERIAL NO. 10/038,006
	APPLICANT DANETTE A. DUDLEY, ET AL.	
	FILING DATE	GROUP 1624

 10/038006
 01/04/02

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
RR	4 0 8 2 7 3 5	4/4/78	Jones et al.	260	112.5 R	
RR	4 0 8 2 7 3 6	4/4/78	Jones et al.	260	112.5 R	
RR	4 8 7 0 1 7 5	9/26/89	Suzuki et al.	544	354	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
RR	1 2 5 4 3 4 8	11.10.89	Japan				x
RR	9 7 0 7 1 1 6	27.02.97	WO				x
RR	63 1 4 5 2 7 2	17.06.88	Japan				x
RR	9 8 0 1 4 2 8	15.01.98	WO				x
RR	9 8 0 1 4 2 8	15.01.98	WO revised version				x
RR	9 7 4 8 7 0 6	24.12.97	WO				x
RR	9 8 1 3 3 6 8	02.04.98	WO				x

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc)

RR	PCT International Search Report, PCT/US98/26704, 1998.
RR	Lappato et al., "X-ray structure of anistatin at 1.9 Å resolution and its modeled complex with blood coagulation factor Xa", <u>The EMBO Journal</u> , Vol. 16, No. 17, 5151-5161, 1987
RR	Mellott et al., "Enhancement of Recombinant Tissue Plasminogen Activator-induced Reperfusion by Recombinant Tick Anticoagulant Peptide, A Selective Factor Xa Inhibitor, in a Canine Model of Femoral Arterial Thrombosis", <u>Fibrinolysis</u> , 7, 1993, 195-202
RR	Lynch et al., "Primary Prevention of Coronary Arterial Thrombosis with the Factor Xa Inhibitor rTAP in a Canine Electrolytic Injury Model", <u>Thrombosis and Haemostasis</u> , 74 (2) 640-5, 1995
RR	Schaffer et al., "Antithrombotic Efficacy of Recombinant Tick Anticoagulant Peptide", <u>Circulation</u> , 1991, 84:1741-1748
RR	Fioravanti, et al., "Antithrombotic Activity of Recombinant Tick Anticoagulant Peptide and Heparin in a Rabbit Model of Venous Thrombosis", <u>Thrombosis Research</u> , 71, 317-324, 1993

EXAMINER	RR	DATE CONSIDERED	9-23-04
----------	----	-----------------	---------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ANY COPIES OF DOCUMENTS LISTED ON THIS FORM PTO-1449 SHOULD HAVE CERTAIN INFORMATION PLACED ALONG THE LEFT SIDE OF THE DOCUMENT. INFORMATION SUCH AS DOCKET NUMBER, FILING DATE, SERIAL NUMBER, ART UNIT, ETC.

FORM PTO-1449 (Rev. 2-32) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 5711-D1-01-MG	SERIAL NO. 10/038,006
	APPLICANT DANETTE A. DUDLEY, ET AL.	
	FILING DATE	GROUP 1624

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc)

RR	Wong et al., "Antithrombotic Actions of Selective Inhibitors of Blood Coagulation Factor Xa in Rat Models of Thrombosis", <u>Thrombosis Research</u> , Vol. 83, No. 2, 117-126, 1996
RR	Edmunds and Rapundalo, "Annual Reports in Medicinal Chemistry, 31, 51-60, 1996
RR	Kunitada and Nagahura, "Factor Xa Inhibitors", <u>Current Pharmaceutical Design</u> , 1996, 2, 531-542
RR	Matuszczak and Mercier, "Syntheses in the series of pyrazolyl-substituted quinoxalines", <u>Heterocycles</u> , Vol. 45, No. 12, 1997, 2449-2462
RR	Leardini et al., "Peroxydicarbonate-Mediated Oxidation of N-(ortho-Aryloxyphenyl) and N-(ortho-Arylaminoxyphenyl)aldimines", <u>Tetrahedron</u> , Vol. 51, No. 44, 12143-12158, 1995
RR	Awad and Hassan, "Studies in Vilsmeier-Haack Reaction. Application to Quinoxalines", <u>Collect. Czech. Chem. Commun.</u> , Vol. 55, 1990, 2715-2721
RR	Otomasu et al., "Quinoxaline 1,2-Dihydroimidazo[1,2-a]-quinoxaline 1,2-Dihydro-3H-pyrimido[1,2-a]quinoxaline", <u>Yakugaku Zasshi</u> , 90 (11), 1391-1395, 1970
RR	Seth et al., "Studies in Antiamoebic Agents: Syntheses of Substituted Indophenazines, Azaindophenazines & Azaquinoxalines", <u>Indian Journal of Chemistry</u> , Vol. 12, 1974, 124-128
RR	Sparatore et al., "Quinolizidine Derivatives as Potential Antitumoral Agents", <u>Il Farmaco</u> , 44 (10), 945-950, 1989
RR	Hahn et al., "Effect of Mepyramine and Spasmolytic Agents on Guinea-Pig Anaphylaxis with Special Reference to the Protracted Shock", <u>Arch. Int. Pharmacodyn.</u> , 199, 108-121, 1972
RR	Chemical Abstracts, Vol. 111, No. 9, 1989, abstract 78027u
RR	Morrow and Regan, "Some Unusual Oxidation Reactions of 1,3-Diaryl-3,4-dihydro-7-methoxy-2(1H)-quinoxalineones", <u>J. Org. Chem.</u> , Vol. 36, No. 1, 1971, 27-31
RR	Kato et al., "Structural Analysis of N-(phenylalkyl)substituted quinoxaline-2(1H)-ones and -thiones", <u>Heterocycles</u> , Vol. 44, No. 1, 1997, 357-366
RR	Kurasawa et al., "Revised Structure for the Production from the Reaction of 3-Hydrazinocarbonylmethylene-2-oxo-1,2,3,4-tetrahydroquinoxaline with Nitrous Acid", <u>Chem. Pharm. Bull.</u> , 32 (10), 4140-4143, 1984

EXAMINER <i>RR</i>	DATE CONSIDERED 9-23-01
-----------------------	----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ANY COPIES OF DOCUMENTS LISTED ON THIS FORM PTO-1449 SHOULD HAVE CERTAIN INFORMATION PLACED ALONG THE LEFT SIDE OF THE DOCUMENT. INFORMATION SUCH AS DOCKET NUMBER, FILING DATE, SERIAL NUMBER, ART UNIT, ETC.